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Abstract. Since various studies, including multi-centre studies, investigating the effect of repetitive transcranial magnetic
stimulation (rTMS) in depression have shown different results, it is now important to research, which symptoms of depression
are most responsive to this kind of non-invasive brain stimulation. Furthermore, an increasing interest of rTMS as a potential tool
for treatment of neurological and psychiatric disorders should be recorded. Therefore, it is critical to investigate dopaminergic
functional interactions in the prefrontal cortex, and in particular, the effect of dorsolateral prefrontal cortex stimulation on
clinical symptoms depending on dopaminergic concentrations in various brain regions. This short review summarizes important
preliminary data, which focus on the symptom-oriented effects of rTMS in depression.
1. Introduction
Repetitive transcranial magnetic stimulation (rTMS)
was introduced as a promising new treatment option
for depression and showed beneficial effects in single-
centre studies (Burt et al., 2002; Kozel and George,
2002; Loo and Mitchell, 2005). To date, numerous
open and controlled clinical trials have demonstrat-
ed that high-frequency (> 5 Hz) rTMS applied over
the left dorsolateral prefrontal cortex (DLPFC) (means
high frequency left – HFL) and low-frequency(< 1 Hz)
rTMS applied over the right DLPFC (means low fre-
∗Correspondint author. E-mail: jacqueline.hoeppner@med.uni-
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quency right – LFR) have antidepressant effects (Ger-
shon et al., 2003). However, it remains difficult to draw
general conclusions about the antidepressant efficacy
of rTMS because of heterogeneous study designs, vari-
able stimulation parameters and low sample sizes (Mar-
tin et al., 2003). In recent years, two important multi-
centre studies (MCS) on higher number of included de-
pressive patients were published (Herwig et al., 2007;
O’Reardon et al., 2007). The aim of these multi-centre
trials was to evaluate whether the application of rTMS
in a routine clinical setting as a complementary treat-
ment to standard antidepressant medication (Herwig et
al., 2007), or as a single treatment in drug resistant pa-
tients (O’Reardon et al., 2007), would have an effect
compared with a sham treatment regarding the num-
ber of responders and the decrease in depression rating
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scores. Presumably due to the distinct study designs,
different results were found (see Scho¨nfeldt-Lecuona
et al. in this special issue). Within the European Multi-
Centre Study, we did not find beneficial effects of rTMS
compared to a sham stimulation condition with regard
to responder rates or changes in the rating scores (Her-
wig et al., 2007).
In conclusion, it is still a matter of debate, whether
HFL rTMS could be useful in treating depression.
Apart from methodological problems including stim-
ulation parameters and inclusion criteria, it is hypoth-
esized, that rTMS has effects on specific depressive
symptoms, which are difficult to assess with standard
diagnostic instruments for depression severity. Most
of the studies on rTMS in depression have investigated
the effect on treatment response rate or the effect on
depression rating scales as a global measure of depres-
sive symptoms. The influence on selective symptoms,
however, has rarely been investigated up to now.
The present article aims to give an overview of some
specific effects of rTMS on typical depressive symp-
toms. The most frequently investigated symptoms in-
fluenced by rTMS, regardless of the underlying disor-
der, are attention and motor signs, which are closely
related to brain dopamine (DA) dysfunction. DA is
implicated in the regulation of movement, attention,
reward and learning, and plays an important role in
neuropsychiatric disorders such as Major Depression
(MD) (Khedr et al., 2006) and Parkinson’s Disease
(PD). Therefore, this article refers to rTMS effects on
dopaminergic dysfunctions in both disorders.
2. Parkinson’s disease and depression
From a pathophysiological and clinical view, PD and
MD are closely related clinical conditions. Results of
several studies indicate that depressive symptoms ap-
pear in an early stage of PD, that depression is associat-
ed with a high risk for PD, and that depressive disorders
are often associated with PD-like motor dysfunction.
With this background, central findings of recent studies
in the field are summarized as follows:
First: MD is a frequent comorbid condition in PD,
prevalent in 31% of PD patients (Brooks and Doder,
2001), and may precede the diagnosis of PD by 10–
20 years (Shiba et al., 2000). Large register studies
have shown that, compared to non-depressed controls,
depressed patients have a 2.2 to 3.1-fold higher risk for
developing PD (Leentjens et al., 2003; Nilsson et al.,
2001; Schuurman et al., 2002).
Second: Psychomotor symptoms similar to typi-
cal motor signs in PD are very common in patients
with MD, have been found to correlate with anhedonia
(Lemke et al., 1999), and can be assessed with the Mo-
tor Agitation and Retardation Scale (MARS) (Sobin et
al., 1998). Psychomotor retardation symptoms rated as
items of the MARS are very similar to Parkinson symp-
toms, including motor slowness, reduced voice volume,
abnormal gait, lack of facial expressivity, delayed onset
of speech, and monotone speech. Psychomotor agita-
tion symptoms include items such as increased axial
truncal movements, abnormal hand, foot and lower leg
movements, tension of the mouth, increased blinking.
Compared to patients without psychomotor signs, pa-
tients with such signs tended to be more severely ill and
have a more complicated course of the depressive disor-
der (Angst et al., 2009). From a pathophysiological per-
spective, an association to DA neurotransmission was
shown in MD patients with psychomotor symptoms. In
[11C]raclopride PET investigations, Meyer et al. found
an elevated putamen D(2)-receptor binding potential in
psychomotor retarded depressed patients (Meyer et al.,
2006). Furthermore, functional neuroimaging findings
also suggest an involvement of the same DA-related
neuroanatomical substrates in patients with MD as in
patients with PD (e.g. striatum, ventrolateral prefrontal
and orbitofrontal cortex) (Tremblay et al., 2005).
In our research group, transcranial brain sonography
(TCS) was used to investigate associations between ab-
normalities in substantia nigra (SN) and clinical motor
functions in depressive patients. TCS has previously
proved reliable in detecting abnormalities of SN and
basal ganglia in PD (Becker et al., 1995; Walter et al.,
2003). In about 90% of PD patients, TCS reveals char-
acteristic SN hyperechogenicity, which remains stable
during the course of the disease and is discussed to re-
flect increased amounts of iron, bound to proteins oth-
er than ferritin, but not the progressive neurodegener-
ation in the SN (Berg et al., 2005; Berg et al., 2002;
Walter et al., 2004; Walter et al., 2003). SN hyper-
echogenicity in non-parkinsonian subjects was found
to be associated with a malfunction of the nigrostriatal
dopaminergic system (Berg et al., 1999; Berg et al.,
2001; Sommer et al., 2004; Walter et al., 2004). In pa-
tients with depressive disorders, SN hyperechogenicity
is found with threefold increased frequency compared
to non-depressed controls (Walter et al., 2007). In our
study on 56 depressed patients, we studied whether SN
hyperechogenicity in depressed subjects is already re-
lated to mild motor abnormalities suggestive of early
stages of PD (Hoeppner et al., 2009). TCS data in
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Fig. 1. Results of a TCS study in 56 depressed patients. Correlation between SN echogenic size in patients with depressive disorder and
right-to-left tapping asymmetry index, estimated by division of larger by smaller tapping score of both hands. SN echogenic size was correlated
with tapping asymmetry index in the group of all patients (r = 0.35, P = 0.017; dashed line), and even stronger if only patients at ages ‡ 50 years
were considered (r = 0.52, P = 0.007; continuous line) but not among patients at ages < 50 years (P = 0.70; dotted line).
this study shows, that SN hyperechogenicity is related
to motor asymmetry (measured with the finger tapping
test), as a characteristic finding of preclinical PD stage
(Fig. 1). This relationship is independent from age, yet
stronger in patients 50 years and older, and stronger in
patients with reduced brainstem raphe (BR) echogenic-
ity. Reduced BR echogenicity in depressed subjects
has been shown to relate to alteration on MRI of the
dorsal raphe nucleus, and to better responsiveness to
serotonin reuptake inhibitors (Becker et al., 2001; Wal-
ter et al., 2007). The underlying mechanisms of motor
asymmetry in depressive patients might be (a) an al-
teration of nigral dopaminergic neurons, indicated by
SN hyperechogenicity, and/or (b) impaired serotonin-
mediated regulation of striatal DA transmission (Alex
et al., 2005), indicated by reduced BR echogenicity.
Third: Patients with PD and MD show similari-
ties in prefrontal brain dysfunctions. The prefrontal
cortex (PFC) is important for screening distractions,
sustaining attention, shifting/dividing attention in a
task-appropriate manner, and is critical for regulat-
ing behaviour, especially for inhibiting inappropriate
emotions, impulses and habits. The PFC is need-
ed for allocating/planning goals and organizing be-
haviour/thought, and it regulates attention and be-
haviour through networks of interconnected pyramidal
cells. These networks excite each other and are high-
ly dependent on their neurochemical environment, for
example, changes in DA can have marked effects on
PFC function (Arnsten, 2009). Due to the dysfunc-
tion in the DLPFC, depressed patients are impaired in
the ability to shift their focus of attention (Silton et
al., 2009). It has been proposed that a dorsal circuit
plays an important role in the interaction between emo-
tional and attentional processing. Neuroimaging stud-
ies have shown the engagement of the left DLPFC in
executive functioning (Johnson et al., 2007), emotion
regulation (Domes et al., 2010; Ochsner et al., 2004)
and its crucial involvement in depression (Koenigs and
Grafman, 2009). Individuals with PD also demonstrate
impairments on tasks relying on the PFC, regarding the
loss of dopaminergic neurons in the SN and the ven-
tral tegmental area, with degeneration of their striatal
terminals, and the resulting dysfunction of the intimate
connections between the striatum and the frontal lobes
(Drag et al., 2009).
3. rTMS effects on dopaminergic
neurotransmission
Concerning the above mentioned observations, it is
critical to investigate dopaminergic functional interac-
tions in the PFC and in particular the effect of DLPFC
stimulation on DA concentration in various brain re-
gions. In a first study in PD patients, the influence
of rTMS on DA and homovanillic acid (HVA) levels
in the lumbar cerebrospinal fluid (CSF), in addition to
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clinical effects was investigated. The results show that
patients receiving frontal rTMS have a significant de-
crease in clinical PD scores and significantly reduced
CSF levels of HVA, which suggest that rTMS may exert
its effect via the dopaminergic systems (Shimamoto et
al., 2001). In animal studies, an elevation of extracel-
lular DA in the striatum has been shown after frontal
rTMS (Keck et al., 2002). In humans, a PET study with
healthy subjects shows that rTMS on the left DLPFC
induced a significant reduction in the [(11)C]FLB 457
binding potential (BP) in the ipsilateral subgenual ante-
rior cingulate cortex (ACC), pregenual ACC and medi-
al orbitofrontal cortex (Cho and Strafella, 2009). There
were no significant changes in [(11)C]FLB 457 BP fol-
lowing right DLPFC rTMS. This study provides evi-
dence of extrastriatal DA modulation in the PFC fol-
lowing acute rTMS of left DLPFC. It is concluded, that
the increase in dopaminergic neurotransmission con-
tributes to the effects of rTMS in the treatment of MD
and PD. Accordingly, a [123I] iodobenzamide (IBZM)
SPECT study with depressed patients found a reduction
of specific striatal IBZM binding to DA D2 receptors
after HFL rTMS (Pogarell et al., 2006).
Further, combining neuroimaging and TMS-studies
might help to identify the neurobiological effects of
TMS for the treatment of different neurological and
psychiatric diseases. In sum, the results of these in-
vestigations suggest that left prefrontal rTMS stimu-
lates the release of endogenous DA, and thereby exerts
modulation of mesolimbic and mesostriatal dopamin-
ergic pathways. Based on this conclusion, effects of
HFL rTMS on DA related clinical symptoms should be
expected.
4. rTMS effects on motor/psychomotor symptoms
Independent of the above discussed findings of
rTMS effects on dopaminergic neurotransmission, mo-
tor symptoms have been the focus of investigations on
clinical TMS effects in PD since 1985 (Elahi et al.,
2009). In a meta-analysis on the effects of rTMS on
motor signs in PD, the mean effect size for 10 includ-
ed studies on the Unified Parkinson’s Disease Rating
Scale (UPDRS) was calculated. Pooling of the results
yielded an average effect size of −0.58 for HF rTMS
studies and no significant effects for LF rTMS studies
(Elahi et al., 2009). However, since the clinical pre-
sentation of PD is related to abnormal neuronal activity
within the basal ganglia and cortical regions, including
the primary motor cortex, the premotor cortex, and the
PFC, the studies have used different rTMS procedures
including different stimulation regions.
As already mentioned above, depression is a fre-
quent comorbid condition in PD. Therefore, the influ-
ence of prefrontal rTMS on motor symptoms in addi-
tion to it effects on depressive symptoms became the
object of investigations. Helmich et al. reviewed TMS
studies investigating therapeutic effects on mood and
motor function in PD patients and highlighted method-
ological inconsistencies, including the difficulty to de-
fine the most effective protocol for rTMS or to estab-
lish an appropriate placebo condition (Helmich et al.,
2006). The results on the HFL rTMS effects in PD pa-
tients are inconsistent. While some HFL rTMS studies
have shown that prefrontal stimulation may be bene-
ficial for depressed PD patients in multiple function-
al domains, i.e. depression scores, anxiety, movement
scores, and some neuropsychological measures (Ep-
stein et al., 2007), others could not confirm these results
(del Olmo et al., 2007) and concluded that prefrontal
rTMS has no effect on motor functions and clinical mo-
tor status, and that the observed improvement in per-
formance of motor tasks could only be attributed to the
effects of practice (del Olmo et al., 2007).
So far, some results in the literature suggest that
rTMS might have a positive effect on clinical symp-
toms associated with striatal dopaminergic dysfunc-
tion. In MD the clinical effects of rTMS on psychomo-
tor symptoms has been rarely investigated up to now.
Our group’s aim is to devote time and research to this
question.
In an initial rTMS study from our laboratory, we in-
vestigated 30 MD patients using two different rTMS
procedures (HFL 20 Hz: 20 Hz rTMS over the left
dorsolateral prefrontal cortex; LFR 1 Hz: 1 Hz rTMS
over the right dorsolateral prefrontal cortex) compared
to sham stimulation (e.g. the coil was placed with an
angle of 90◦ in relation to the head, stimulation in-
tensity was reduced – for details see: (Hoeppner et
al., 2003)) (10 patients in each group) over 10 days
(Hoeppner et al., 2003). We measured the effect on
depressive rating scales and the effects on psychomotor
functioning. Psychomotor impairments were assessed
with the MARS (Sobin et al., 1998). Patients of the
sham-stimulated group show, on average, no reduction
of psychomotor functions. Within the 20 Hz rTMS
group, the improvement of MARS score was statistical-
ly significant after 5 days (t = 3.33; p < 0.001), with a
further improvement at the end of rTMS-treatment (t =
6.98; p < 0.001). The MARS-scores of the patients
of the 1 Hz rTMS group show a reduction exclusively
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Fig. 2. Comparison of pre- to post-treatment MARS scores in our first rTMS study using two different rTMS procedures (high frequency left
= HFL 20 Hz/low frequency right = LFR 1 Hz) compared to a sham stimulation. One-sample t-test showed, that in the group receiving 20 Hz
rTMS over the left dorsolateral prefrontal cortex (HFL 20 Hz) the improvement of MARS sum score was statistically significant between baseline
and endpoint score (t = 6.98; p < 0.001). The MARS score of the patients of the group receiving the 1 Hz rTMS over the right dorsolateral
prefrontal cortex (LFR 1 Hz) showed a less statistical powerful reduction (t = 2.73; p = 0.023), whereas the reduction was not statistically
significant in the sham stimulated patients group. ∗p  0.05; ∗∗∗p  0.001.
after 10 days (t = 2.73; p = 0.023) (Fig. 2). However,
no differentiation is drawn between psychomotor agi-
tation and retardation (Hoeppner et al., 2003). In ad-
dition, the groups were not comparable regarding their
antidepressant medication. Patients were left on their
antidepressant medication on which they failed to show
clinical effects. The medication was not changed two
weeks before and during the rTMS procedure.
The aim of our second study was to investigate the
effect of HFL (10 Hz) rTMS on psychomotor dysfunc-
tion, and in addition, to investigate the differential in-
fluence on psychomotor retardation and on psychomo-
tor agitation in MD patients (Hoeppner et al., 2009).
The data were collected as part of a recent random-
ized, double-blind, sham-controlled, multi-center trial
investigating the antidepressant effects of augmentative
rTMS (Herwig et al., 2007) (see also in Schoenfeldt-
Lecuona et al. in this special issue). Based on our initial
findings, we hypothesize that rTMS will improve both
psychomotor agitation and retardation.
Inclusion criteria were: age 18–75 years, a moderate
or severe major depressive episode according to ICD-
10 and DSM-IV (SCID), and a score of 18 points or
more in at least two of the three depression rating scales:
Becks’ Depression Inventory (BDI), Hamilton Depres-
sion Scale (HAM-D 21-items version), Montgomery-
Åsberg Depression Rating-Scale (MADRS). Thirty pa-
tients (18 females, mean age: 52.3 ± 11.9 years) were
investigated at two participating centers of the multi-
center study (Psychiatric Departments of the Universi-
ties of Rostock and Munich). The patients were ran-
domly assigned to either a real stimulation or a sham
stimulation group. Details regarding the inclusion and
exclusion criteria have been described previously (Her-
wig et al., 2007). In order to integrate rTMS in a natu-
ralistic routine clinical setting, and for ethical and safe-
ty reasons, rTMS was applied parallel to a standard-
ized antidepressant medication. The stimulation ses-
sions were started together with a venlafaxine or mir-
tazapine treatment, both selected because of their com-
bined serotonergic and noradrenergic profile in order to
rule out neurotransmitter-specific confounding effects.
Other antidepressants, neuroleptics or anticonvulsants
were not allowed, lorazepam was only permitted as
an exceptional crisis medication. Both groups did not
differ either in terms of age, clinical baseline charac-
teristics, in concomitant antidepressant medication, in
dosage of antidepressants nor in the severity of depres-
sion. Unfortunately, but accidentally, there were signif-
icantly more women in the real, than in the sham stimu-
lation group (real: 13/sham: 5) (χ2 = 8.89, p = 0.01).
Again, the MARS was used to evaluate psychomotor
symptoms. Group differences were tested with Stu-
dent’s t-test (one tailed) for independent samples. As
the main result, we found a significant reduction of
the agitation after real compared to sham stimulation
(t = −1.8, p = 0.045; single-tailed), although the real
stimulation group showed higher pre-treatment scores
582 J. Ho¨ppner et al. / Influence of repetitive transcranial magnetic stimulation on special symptoms
-10
-5
0
5
10
15
20
25
30
35
40
10 Hz sham
*
MARS sum Agitation Retardation 
% N=2x10
Fig. 3. Relative change in % of the MARS sumscore, agitation and retardation subscores. Comparison between real (10 Hz HFL) and sham
stimulation groups. Significant reduction of the agitation after real compared to sham stimulation (one tailed t-test: p = 0.045), no statistical
significant differences in MARS sumscore and retardation score.
(t = 2.19, p = 0.037) (Fig. 3). When considering the
course of scores within the groups, we found a sig-
nificant difference between pre- and post-stimulation
scores in the real stimulation group (p = 0.002), which
was not the case in the sham group (p = 0.061). The
Mann-Whitney-U exact test revealed a trend towards an
enhanced improvement (pre- to post-agitation scores)
in the group comparison (p = 0.053, one tailed). Ana-
lyzing effect sizes, we found a medium effect of rTMS
on agitation compared to sham stimulation (absolute
change; Cohen’s d = 0.66). There were no group dif-
ferences for the total and the retardation score of the
MARS. Furthermore, there were no significant differ-
ences between patients who received venlafaxine (n =
14) and those who received mirtazapine (n = 16) on
the absolute changes of psychomotor symptoms irre-
spective of the rTMS condition (MARS sum score:
t = −0.73, p = 0.47; agitation score: t = −0.08,
p = 0.93; retardation score: t = −1.03, p = 0.31).
Regarding the depression rating scales, there were no
significant differences in clinical ratings of depression
severity, measured with BDI, HDRS and MADRS.
5. Discussion and summary
Starting from our own neurobiological studies
on psychomotor dysfunctions in depressive patients,
which suggest alterations of nigral dopaminergic neu-
rons, indicated by SN hyperechogenicity in TCS
(Hoeppner et al., 2009; Walter et al., 2007), and nu-
merous other investigations on this topic, and from an-
imal and human studies, which show an influence of
HFL rTMS on dopaminergic neurotransmission, we in-
vestigated the effect of rTMS on underlying clinical
symptoms such as psychomotor dysfunctions.
Although we did not observe significant differences
between real and sham stimulation conditions with re-
gard to the overall severity of depression in both of
our rTMS studies (Hoeppner et al., 2009; Hoeppner et
al., 2003), a trend toward the overall improvement of
psychomotor symptoms after real, especially after HFL
rTMS, compared to sham stimulation (Hoeppner et al.,
2003), and in addition, a significant reduction of a cer-
tain domain of psychomotor functioning (psychomotor
agitation) was found after real rTMS compared to sham
stimulation (Hoeppner et al., 2009).
Based on the results of our second rTMS study
(Hoeppner et al., 2009), that differentiated between
special psychomotor dysfunction in depressed patients,
and shows reduction in agitation but not, as was ex-
pected, in retardation, other pathways, different from
release of endogenous DA, should be discussed. In ad-
dition, serotonin neurotransmission deficits are thought
to be involved in agitation and hyperactivity (Brus et
al., 2004). Neurochemical investigations have shown
an effect of rTMS on serotonergic neurotransmission:
high-frequency frontal rTMS in rats resulted in an in-
crease of extracellular 5-HT concentration in the pre-
frontal cortex (Kanno et al., 2003). Furthermore, dys-
functions of the hypothalamic-pituitary-adrenocortical
(HPA) axis should be discussed. Rubin et al. have
shown that agitation in depression correlates with in-
creased HPA activity (Rubin et al., 1987), and rTMS
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has been reported to suppress post-dexamethasone cor-
tisol levels in rTMS-responsive MD patients (Zwanzger
et al., 2003). Hence, modulation of HPA and seroton-
ergic functioning by rTMS could be responsible for the
influence of HFL rTMS on psychomotor agitation.
Some methodological problems in both of our rTMS
studies should be mentioned, which are most likely due
to the fact that the studies were conducted in a real
common sample of depressed in-patients. We should
mention the small sample sizes. In clinical routine set-
tings and in single-centre trials, it is obviously chal-
lenging to recruit large samples of patients who fulfill
the inclusion criteria, agree to the study conditions, and
do not take anticonvulsants, neuroleptics and benzodi-
azepines. In addition, the different gender ratio (more
female patients in the real compared to the sham rTMS
group) and the use of two different antidepressant med-
ications in our second rTMS study (Hoeppner et al.,
2009) should be critically discussed.
Nevertheless, our findings provide new evidence that
psychomotor symptoms in depression could be respon-
sive to HFL rTMS. The mechanism of action, however,
has to be elucidated in more detail. For further stud-
ies it would be of great interest to investigate specif-
ic symptoms of depression, which depend on certain
neurobiological alterations and pathophysiologic brain
dysfunctions. Therefore, combining rTMS, clinical,
neuroimaging and neurochemical investigations might
be a promising approach.
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